Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK564289PMID: 33226752
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 937263-43-9
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of tucatinib during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tucatinib therapy and for 1 week after the last dose. However, tucatinib is used in combination with trastuzumab and capecitabine. It is recommended that breastfeeding be suspended for 7 months after the use of trastuzumab.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Tucatinib
CAS Registry Number
937263-43-9
Drug Class
Breast Feeding
Lactation
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.[Lancet Oncol. 2018]Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Lancet Oncol. 2018 Jul; 19(7):880-888. Epub 2018 May 24.
- Review Brigatinib.[Drugs and Lactation Database (...]Review Brigatinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Ceritinib.[Drugs and Lactation Database (...]Review Ceritinib.. Drugs and Lactation Database (LactMed®). 2006
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.[Ann Oncol. 2022]Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, et al. Ann Oncol. 2022 Mar; 33(3):321-329. Epub 2021 Dec 23.
- Review Venetoclax.[Drugs and Lactation Database (...]Review Venetoclax.. Drugs and Lactation Database (LactMed®). 2006
- Tucatinib - Drugs and Lactation Database (LactMed®)Tucatinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...